Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi

In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.

From DESTINY-Breast 09 to real-world decision-making, they discuss what a 40-month median PFS truly means, how T-DXd compares to THP, and whether “if it ain’t broke, don’t fix it” still applies.

They also tackle sequencing strategies, maintenance vs continuous therapy, PIK3CA resistance, and how patient quality of life is shaping long-term treatment decisions.

A must-watch episode for clinicians navigating the rapidly evolving HER2+ landscape.